文献速递头颈与中枢神经肿瘤支持与姑息治疗

未分化甲状腺癌患者诊疗现状与可满足需求:EORTC内分泌与头颈癌症组94家机构的调查

Current picture of anaplastic thyroid cancer patients' care and meetable needs: A survey of 94 Institutions from the EORTC Endocrine and Head and Neck Cancer Groups.
PubMed 文献 · Eur J Cancer · 2022-12-11

该调查于2021年3月12日至19日面向EORTC内分泌与头颈癌症组的239家机构,了解未分化甲状腺癌(ATC)患者年评估量、BRAF检测可行性、BRAF/MEK抑制剂(B/Mi)与免疫治疗(IO)可及性及临床试验情况。94家机构(20个国家)回应,30家每年评估≥5例ATC患者,年总发病率>200例;80.8%检测BRAF状态,43.6%采用二代测序;62.7%和70%的应答者分别报告B/Mi和IO处方受限;仅13.8%有正在进行的临床试验,而91.5%的机构声称需要ATC专用试验。作者认为新治疗可及性差异普遍存在,在适当网络内开展临床试验似乎可行。

要点

  • 94家机构(20个国家)参与调查,30家每年评估≥5例ATC患者,年总发病率>200例。
  • 80.8%的机构检测BRAF状态,其中43.6%采用二代测序。
  • 62.7%和70%的应答者分别报告B/Mi和IO处方受限;仅13.8%有正在进行的临床试验。

核心结论

  • 新治疗可及性差异普遍存在,获取前沿治疗是该场景的紧迫问题,在适当网络内临床试验似乎可行。

研究设计与样本

  • 在线调查于2021年3月12日至19日面向EORTC内分泌与头颈癌症组的239家机构开放。
  • 调查问题包括每年评估的ATC患者数、BRAF评估可行性、B/Mi-IO可及性、临床试验可用性及对新研究的兴趣。

主要发现

  • 94家机构(20个国家)参与,30家每年评估≥5例ATC患者,年总发病率>200例。
  • 80.8%的机构检测BRAF状态,43.6%采用二代测序。
  • 62.7%和70%的应答者分别报告B/Mi和IO处方受限:或无法提供,或仅在特定条件下可及(如医疗保险、临床试验、同情用药、超说明书用药)。
  • 仅13.8%的机构有正在进行的临床试验,而91.5%的机构声称需要ATC专用试验。

关键数值与推荐

  • TMB-H定义为≥10个突变/兆碱基(mut/Mb)。
  • FDA已批准B/Mi用于BRAFV600E突变ATC,批准帕博利珠单抗用于TMB-H(≥10 mut/Mb)实体瘤;EMA尚未批准B/Mi或IO用于ATC。

临床怎么用

  • 部分患者通过替代途径获得这些药物。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Anaplastic thyroid carcinoma (ATC) is a rare cancer accounting for 40% of thyroid cancer-specific deaths. In the last 5 years, improved insights into molecular pathways led the Food and Drug Administration to license BRAF/MEK inhibitors (B/Mi) in BRAFV600E-mutant ATC, and pembrolizumab in solid cancer with high tumour mutational burden (TMB-H) (≥10 mutations/megabase) (mut/Mb). In Europe, clinicians face challenges in prescribing novel treatments, as the European Medical Association (EMA) has not licensed B/Mi nor immunotherapy (IO) for ATC so far. Some patients manage to receive these drugs through alternative ways. We investigated the extent of this phenomenon launching an online survey from March 12th to 19th 2021 open to 239 Institutions in the EORTC Endocrine and Head & Neck Cancer Groups. Questions enquired about the number of ATC patients evaluated/year, feasibility of BRAF assessment, accessibility to B/Mi-IO, availability of clinical trials and interest in new studies. Colleagues from 94 Institutions (20 Countries) joined: 30 centres evaluated ≥5 ATC patients/year, with an overall incidence >200 patients/year. 80.8% tested BRAF status, 43.6% by next-generation sequencing. 62.7% and 70% of responders reported limitations in prescribing B/Mi and IO, respectively: either the impossibility of offering them, or drugs accessibility exclusively under certain conditions (e.g. health insurance, clinical trials, compassionate use, off-label). Only 13.8% had clinical trials ongoing while 91.5% of sites claimed ATC-dedicated trials. Disparities in access to novel treatments are diffuse. Access to cutting-edge therapies is an urgent issue in this setting, and clinical trials seem feasible within an appropriate network.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Locati LD, Colombo E, Dedecjus M, et al. Current picture of anaplastic thyroid cancer patients' care and meetable needs: A survey of 94 Institutions from the EORTC Endocrine and Head and Neck Cancer Groups. Eur J Cancer. 2022. PMID: 36599182. doi:10.1016/j.ejca.2022.12.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。